MDGL Insider Trading Activity and SEC Form 4 Filings
MDGL insider trading summary
Over the past 12 months, insiders at Madrigal Pharmaceuticals, Inc. (MDGL) reported 191 sales worth $73.4M by 8 insiders and no open-market purchases on SEC Form 4. Net insider selling was $73.4M.
Latest MDGL insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 6, 2026 | Shannon T Kelley | General Counsel | Sell | $431K (1,077 @ $400.00) |
| Sep 11, 2026 | William John Sibold | President and CEO | Sell | $415K (761 @ $544.83) |
| Sep 11, 2026 | William John Sibold | President and CEO | Sell | $32K (60 @ $533.09) |
| Sep 11, 2026 | William John Sibold | President and CEO | Sell | $371K (687 @ $540.59) |
| Sep 11, 2026 | William John Sibold | President and CEO | Sell | $652K (1,202 @ $542.60) |
| Sep 11, 2026 | William John Sibold | President and CEO | Sell | $837K (1,539 @ $544.02) |
| Sep 11, 2026 | William John Sibold | President and CEO | Sell | $117K (218 @ $535.94) |
| Sep 11, 2026 | William John Sibold | President and CEO | Sell | $57K (106 @ $534.06) |
| Sep 11, 2026 | William John Sibold | President and CEO | Sell | $86K (160 @ $537.62) |
| Sep 11, 2026 | William John Sibold | President and CEO | Sell | $199K (368 @ $541.64) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.